Malignant biliary obstruction
Conditions
Interventions
Rifaximin:Rifaximin was taken orally 3 times a day, 1 capsule each time
control :No special intervention
Sponsors
Affiliated Drum Tower Hospital of Nanjing University Medical School
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1, Sign the informed consent, serum total bilirubin > 32 umol/L; 2, Patients aged 18-80 years with radiographic evidence consistent with clinical manifestations of malignant biliary obstruction; 3, Patients with middle and advanced cholangiocarcinoma, pancreatic cancer, ampulla carcinoma and other patients requiring ERCP drainage surgery due to obstructive jaundice;
Exclusion criteria
Exclusion criteria: 1, Benign stenosis, stone induced obstructive jaundice, poor coagulation function; 2, Patients with severe septic shock resulting in multiple organ failure who cannot tolerate surgery; 3, Patients with poor cooperation, inability to cooperate with or refusal to undergo surgical treatment; 4, No biliary stent was placed during the operation, or patients with preoperative cholangitis were included.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total bilirubin;Decrease in jaundice 1 month postoperatively; | — |
Secondary
| Measure | Time frame |
|---|---|
| Occurrences of cholangitis during follow-up; | — |
Countries
China
Contacts
Public ContactWang Yi
Affiliated Drum Tower Hospital of Nanjing University Medical School
Outcome results
None listed